Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

USB Piper Downgrades MedImmune to 'Outperform'

USB Piper downgraded MedImmune (MEDI) to outperform.

Analyst Mark Schoenebaum says he hadn't expected Wal-mart's decision to not offer the FluMist vaccination in stores this year. He says the news dents his thesis that FluMist sales will significantly beat the Street's expectations this year. As a result, he lowered the five million 2003 dose estimate to four million.

Schoenebaum says he downgraded MedImmune to outperform from strong buy; he maintains a positive rating because he continues to believe that the earnings power of FluMist has been significantly underestimated by the Street, and that peak FluMist doses will approach 20 million. He thinks the product will fuel 23% earnings per share growth over the next three to five years. Schoenebaum has a $42 target.

blog comments powered by Disqus